Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by 18F-BMS-986192 PET: pooled analysis of data from four solid tumor types
Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Introduction Immune checkpoint inhibitors (ICIs) can elicit anticancer immune responses, but predictive biomarkers are needed. We measured programmed death ligand 1 (PD-L1) expression in organs and lymph nodes using 18F-BMS-986192 positron emission tomography (PET)-imaging and looked for correlations with response and immune-related adverse events. Methods Four 18F-BMS-986192 PET studies in patients with melanoma, lung, pancreatic and oral cancer, receiving ICI treatment, were combined. Imaging data (organ standardized uptake value (SUV)mean, lymph node SUVmax) and clinical data (response to treatment and incidence of immune-related adverse events) were extracted. Results Baseline PD-L1 uptake in the spleen was on average higher in non-responding patients than in responders (spleen SUVmean 16.1±4.4 vs 12.5±3.4, p=0.02). This effect was strongest in lung cancer, and not observed in oral cancer. In the oral cancer cohort, benign tumor-draining lymph nodes (TDLNs) had higher PD-L1 uptake (SUVmax 3.3 IQR 2.5-3.9) compared with non-TDLNs (SUVmax 1.8, IQR 1.4-2.8 p=0.04). Furthermore, in the same cohort non-responders showed an increase in PD-L1 uptake in benign TDLNs on-treatment with ICIs (+15%), while for responders the PD-L1 uptake decreased (−11%). PD-L1 uptake did not predict immune-related adverse events, though elevated thyroid uptake on-treatment correlated with pre-existing thyroid disease or toxicity. Conclusion PD-L1 PET uptake in the spleen is a potential negative predictor of response to ICIs. On-treatment with ICIs, PD-L1 uptake in benign TDLNs increases in non-responders, while it decreases in responders, potentially indicating a mechanism for resistance to ICIs in patients with oral cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Exploring the predictive potential of programmed death ligand 1 expression in healthy organs and lymph nodes as measured by <sup>18</sup>F-BMS-986192 PET: pooled analysis of data from four solid tumor types
- Date Crossref
- 01/06/2024
- Éditeur
- BMJ
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Amsterdam UMC Location Vrije Universiteit Amsterdam pays non établi dans la noticeÉtablissement de santé
-
University Medical Center Groningen pays non établi dans la noticeÉtablissement de santé
-
The Netherlands Cancer Institute pays non établi dans la noticeÉtablissement de santé
-
Department of Medical Oncology pays non établi dans la noticeInstitution
-
Imaging and Biomarkers pays non établi dans la noticeInstitution
-
Department of Radiology and Nuclear Medicine pays non établi dans la noticeInstitution
-
Cancer Biology and Immunology pays non établi dans la noticeInstitution
-
Otolaryngology / Head and Neck Surgery pays non établi dans la noticeOrganisation à but non lucratif
-
University Medical Centre Groningen Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
NKI pays non établi dans la noticeInstitution
Amsterdam UMC Location Vrije Universiteit Amsterdam, University Medical Center Groningen et The Netherlands Cancer Institute, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.